The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings.
Novo Nordisk said it will slash list prices of the blockbuster diabetes and weight-loss medications Ozempic, Rybelsus, and Wegovy to $675 for a one-month supply effective Jan. 1, 2027. All three medications currently carry list prices of more than $1,000 for a one-month supply, with Wegovy injections and pills the priciest at $1,349.
The price cuts won't have any effect on consumers who pay cash for their weight-loss medications. Novo Nordisk officials said the price cuts are aimed at making the drug more affordable for consumers with insurance plans that link coverage to the medications' list price.
The price cuts also come as Novo Nordisk faces intense competition from Eli Lilly, the drugmaker whose obesity drug, Zepbound, has captured a growing share of the weight-loss market.
On Feb. 23, Novo Nordisk released late-stage study results showing participants who took its next-generation obesity drug, CagriSema, didn't lose as much weight as those who took rival Eli Lilly's Zepbound. Novo Nordisk's shares dropped 16% on Monday after releasing the head-to-head results of weight-loss medications.
